External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Pre-Eclampsia

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Jan 30 / Roche
Reference range for Elecsys sFlt-1/PlGF ratio in a diverse U.S population
The sFlt-1/PlGF ratio test is used for the clinical prediction of preeclampsia in many countries worldwide but has not been widely adopted in the US. This study aimed to determine the reference range for the Roche Elecsys sFlt-1/PlGF ratio (electrochemiluminescent immunoassays) in a racially and ethnically diverse healthy US population of pregnant women at 23+0 - 34+6 gestational weeks.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 25 / Roche
Circulating angiogenic factors for stratifying the risk of preeclampsia with severe features
Study aims to validate the Elecsys sFlt-1/PlGF ratio, at the cut-off of 38, for the prediction of severe preclampsia within two weeks in the prospective PRAECIS cohort study.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 10 / Roche
Angiogenic biomarkers in pregnant women with suspected preeclampsia: A health economics review
As summary of the potential uses of angio-genic biomarker testing for the prediction, diagnosis and prognosis of preeclampsia and adverse pregnancy outcomes and a review of published studies on the health economics of angiogenic biomarker testing.
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback